MX385589B - RÉGIMEN DE DOSIFICACIÓN PARA ANTAGONISTAS DE MAdCAM. - Google Patents
RÉGIMEN DE DOSIFICACIÓN PARA ANTAGONISTAS DE MAdCAM.Info
- Publication number
- MX385589B MX385589B MX2017009047A MX2017009047A MX385589B MX 385589 B MX385589 B MX 385589B MX 2017009047 A MX2017009047 A MX 2017009047A MX 2017009047 A MX2017009047 A MX 2017009047A MX 385589 B MX385589 B MX 385589B
- Authority
- MX
- Mexico
- Prior art keywords
- dosing regimen
- madcam
- patient
- antagonists
- madcam antagonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
Abstract
La presente invención se refiere a un anticuerpo antagonista de MAdCAM para usarse en el tratamiento de colitis ulcerativa en un paciente, en donde el anticuerpo antagonista de MAdCAM se administra por vía subcutánea al paciente en una dosis incial de 22.5 mg o 75 mg del anticuerpo antagonista de MAdCAM seguido de una o más dosis posteriores del anticuerpo antagonista de MAdCAM en una cantidad que es aproximadamente la misma que la dosis inicial, en donde una o más dosis posteriores se dosifican aproximadamente cada 4 semanas, en donde el anticuerpo antagonista de MAdCAM comprende una CDR1 de cadena ligera de SEQ ID NO: 11; una CDR2 de cadena ligera de SEQ ID NO: 12; y una CDR3 de cadena ligera de SEQ ID N O: 13, y una CDR1 de cadena pesada de SEQ ID NO:14; una CDR2 de cadena pesad de SEQ ID NO: 15; y una CDR3 de cadena pesada de SEQ ID NO: 16, y en donde la tasa de remisión clínica observada aproximadamente 12 semanas después de la dosis inicial, según se determina usando la puntuación MAYO, es de al menos aproximadamente 10%.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562101877P | 2015-01-09 | 2015-01-09 | |
| US201562263197P | 2015-12-04 | 2015-12-04 | |
| US201562263910P | 2015-12-07 | 2015-12-07 | |
| PCT/IB2016/050047 WO2016110806A2 (en) | 2015-01-09 | 2016-01-06 | Dosage regimen for madcam antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017009047A MX2017009047A (es) | 2019-01-30 |
| MX385589B true MX385589B (es) | 2025-03-12 |
Family
ID=55275128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017009047A MX385589B (es) | 2015-01-09 | 2016-01-06 | RÉGIMEN DE DOSIFICACIÓN PARA ANTAGONISTAS DE MAdCAM. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10851163B2 (es) |
| EP (2) | EP3242684B1 (es) |
| JP (2) | JP6779621B2 (es) |
| KR (1) | KR102756784B1 (es) |
| CN (3) | CN114377125A (es) |
| AU (2) | AU2016205852B2 (es) |
| BR (1) | BR112017014793A2 (es) |
| CA (1) | CA2916283C (es) |
| CL (1) | CL2017001756A1 (es) |
| EA (1) | EA037288B1 (es) |
| ES (1) | ES2927958T3 (es) |
| IL (1) | IL253247B (es) |
| MA (1) | MA41314A (es) |
| MX (1) | MX385589B (es) |
| SG (1) | SG11201705604WA (es) |
| WO (1) | WO2016110806A2 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6904905B2 (ja) * | 2014-12-24 | 2021-07-21 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | 抗α4β7インテグリン抗体による治療の結果の予測 |
| CA2916283C (en) * | 2015-01-09 | 2024-07-02 | Pfizer Inc. | MADCAM ANTAGONIST DOSING REGIMEN |
| AU2018273914A1 (en) * | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| KR102787394B1 (ko) | 2017-07-14 | 2025-03-26 | 화이자 인크. | MAdCAM에 대한 항체 |
| CN108118093A (zh) * | 2018-03-06 | 2018-06-05 | 谢琳 | Linc00426在制备骨肉瘤转移诊断产品中的用途 |
| US20210030868A1 (en) * | 2019-07-29 | 2021-02-04 | Cai Gu Huang | Formulation of antibody based drugs for treating lung cancer by inhalation |
| CN114164211B (zh) * | 2021-09-16 | 2024-02-27 | 中国人民解放军海军军医大学 | lncRNA及其在肿瘤诊断、治疗和预后判断中的应用 |
| CN113789328A (zh) * | 2021-09-16 | 2021-12-14 | 中国人民解放军海军军医大学 | lncRNA及其在免疫调控及免疫相关疾病诊治中的应用 |
| CN116631510B (zh) * | 2022-10-28 | 2024-01-12 | 中国人民解放军军事科学院军事医学研究院 | 一种用于鉴别诊断克罗恩病和溃疡性结肠炎的装置 |
| JP2025538586A (ja) * | 2022-11-22 | 2025-11-28 | 武田薬品工業株式会社 | 非アルコール性脂肪性肝炎の治療のためのMAdCAM-1抗体の投薬レジメン |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5698679A (en) * | 1994-09-19 | 1997-12-16 | National Jewish Center For Immunology And Respiratory Medicine | Product and process for targeting an immune response |
| US6551593B1 (en) | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
| US7803904B2 (en) * | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| US6217552B1 (en) | 1999-03-01 | 2001-04-17 | Coaxia, Inc. | Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma |
| US20070202097A1 (en) * | 2003-03-10 | 2007-08-30 | Krissansen Geoffrey W | Monoclonal Antibodies That Recognise Mucosal Addressin Cell Adhesion Molecule-1 (Madcam-1), Soluble Madcam-1 And Uses Thereof |
| DOP2005000002A (es) * | 2004-01-09 | 2005-08-15 | Pfizer | "anticuerpos contra madcam" |
| EP1865986B1 (en) * | 2005-03-08 | 2016-02-17 | Pfizer Products Inc. | Anti-ctla-4 antibody compositions |
| US20100119517A1 (en) | 2005-07-08 | 2010-05-13 | Pfizer Inc | Use of Anti-MAdCAM Antibodies for the Treatment of Coeliac Disease and Tropical Sprue |
| PE20070374A1 (es) | 2005-07-08 | 2007-05-12 | Pfizer Ltd | ANTICUERPOS ANTI-MAdCAM |
| WO2007007160A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat fever |
| WO2007007152A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat metastatic cancers and chloroma |
| WO2007007151A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Use of anti-mad-cam antibody for the treatment of emphysema |
| WO2007007159A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat uterine disorders |
| US8188235B2 (en) | 2008-06-18 | 2012-05-29 | Pfizer Inc. | Antibodies to IL-6 and their uses |
| DE102010013830A1 (de) * | 2010-03-26 | 2011-09-29 | Carl Zeiss Microlmaging Gmbh | Mikroskop und Verfahren zur mikroskopischen Erfassung von Licht einer Probe |
| JP6615745B2 (ja) * | 2013-03-27 | 2019-12-04 | ジェネンテック, インコーポレイテッド | ベータ7インテグリンアンタゴニストによる胃腸炎症障害の治療を評価するためのバイオマーカーの使用 |
| CA2916283C (en) * | 2015-01-09 | 2024-07-02 | Pfizer Inc. | MADCAM ANTAGONIST DOSING REGIMEN |
-
2015
- 2015-12-23 CA CA2916283A patent/CA2916283C/en active Active
-
2016
- 2016-01-05 MA MA041314A patent/MA41314A/fr unknown
- 2016-01-06 EP EP16702586.5A patent/EP3242684B1/en active Active
- 2016-01-06 CN CN202111331776.8A patent/CN114377125A/zh active Pending
- 2016-01-06 ES ES16702586T patent/ES2927958T3/es active Active
- 2016-01-06 AU AU2016205852A patent/AU2016205852B2/en active Active
- 2016-01-06 KR KR1020177021819A patent/KR102756784B1/ko active Active
- 2016-01-06 BR BR112017014793A patent/BR112017014793A2/pt not_active Application Discontinuation
- 2016-01-06 MX MX2017009047A patent/MX385589B/es unknown
- 2016-01-06 EP EP22179107.2A patent/EP4112079A1/en active Pending
- 2016-01-06 CN CN201680014443.3A patent/CN107427576A/zh active Pending
- 2016-01-06 CN CN202111331779.1A patent/CN114732899A/zh active Pending
- 2016-01-06 WO PCT/IB2016/050047 patent/WO2016110806A2/en not_active Ceased
- 2016-01-06 US US15/542,110 patent/US10851163B2/en active Active
- 2016-01-06 EA EA201791227A patent/EA037288B1/ru unknown
- 2016-01-06 SG SG11201705604WA patent/SG11201705604WA/en unknown
- 2016-01-07 JP JP2016001684A patent/JP6779621B2/ja active Active
-
2017
- 2017-06-29 IL IL253247A patent/IL253247B/en unknown
- 2017-07-03 CL CL2017001756A patent/CL2017001756A1/es unknown
-
2020
- 2020-10-14 JP JP2020173121A patent/JP7142200B2/ja active Active
- 2020-11-30 US US17/107,228 patent/US11884726B2/en active Active
-
2021
- 2021-10-12 AU AU2021250850A patent/AU2021250850B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017009047A (es) | Regimen de dosificacion para antagonistas de madcam. | |
| CY1124787T1 (el) | Αντισωματα anti-gitr και μεθοδοι χρησης αυτων | |
| CY1125326T1 (el) | Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων. | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| EA201892119A1 (ru) | Лекарственный препарат, полученный путем комбинирования агониста fxr и arb | |
| EA201690633A1 (ru) | Способы и композиции, включающие комбинацию антагониста vegf и анти-ctla-4 антитела | |
| EA201892294A1 (ru) | Антитела и композиции против tim-3 | |
| EA201692285A8 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
| EA201791093A1 (ru) | Антитела к cd47, способы и применение | |
| MX384141B (es) | Métodos para monitorear y terapias para usarse en tratar el cáncer. | |
| HUE057877T2 (hu) | Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására | |
| MX390878B (es) | Usos medicos de antagonista de ligando 1 de muerte programada (pd-l1). | |
| PH12014501122A1 (en) | Methods of treatment using an antibody against interferon gamma | |
| MX385872B (es) | Uso de un anticuerpo que tiene la capacidad para ligarse a clnd 6 en el tratamiento o prevención de cáncer | |
| EA201690159A1 (ru) | Способы и композиции для лечения рака | |
| CY1120751T1 (el) | Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων | |
| EA201691674A1 (ru) | 1,2-замещенные циклопентаны в качестве антагонистов рецептора орексина | |
| EA201590359A1 (ru) | Лечение ревматоидного артрита | |
| IL251136A0 (en) | Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies | |
| WO2016066634A3 (en) | Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer | |
| MX2017003216A (es) | Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica. | |
| EA201892265A1 (ru) | Способы лечения офтальмологических заболеваний | |
| SG10201805646WA (en) | Angiopoietin-like 4 antibodies and methods of use | |
| EP4342544A3 (en) | Enhancing the therapeutic activity of an immune checkpoint inhibitor | |
| IL291661A (en) | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |